PRMT5/MEP50, Biotin-Labeled Recombinant

• Background:

  Three types of arginine methylation exist in mammalian cells: monomethylarginine (MMA), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) . Type I PRMTs ((CARM1, PRMT1, PRMT2, PRMT3, PRMT6, and PRMT8) catalyze ADMA, while type II PRMTs (e.g. PRMTs 5 and 7) catalyze SDMA.Type II PRMTs are found to be strongly implicated in diseases like cancer.For example, PRMT5 plays a role in the repression of certain tumor suppressor genes such as RB tumor suppressors while PRMT7 overexpression is observed in breast cancer

• Description:

  PRMT5/MEP50 complex of human PRMT5 (GenBank Accession No. NM_006109), amino-acids 2-637 (end), with N-terminal FLAG-Avi tag, MW=74 kDa, and human MEP50 (GenBank Accession No. NM_024102) with N-terminal His-Tag, amino-acids 2-342 (end), MW=38 kDa, coexpressed in HEK293 cells and enzymatically biotin-labeled using Avi-tag™ technology.This product has beencited 2 times.

• UniProt:

  PRMT5: O14744; MEP50: Q9BQA1

• Tag:

  PRMT5: N-terminal FLAG-Avi-Tag; MEP50: N-terminal His-Tag

• Purity:

  ≥ 90%

• Format:

  Aqueous buffer solution

• Shipping Conditions:

  -80°C

• Storage Conditions:

  At least 6 months at –80°C. Avoid freeze/thaw cycles. Storing diluted enzyme is not recommended, if necessary, use carrier protein (BSA 0.1 – 0.5%) .

• Calculated Molecular Weight:

  PRMT5: 74 kDa; MEP50: 38 kDa

• Formulation:

  40 mM Tris-HCl pH 8.0,110 mM NaCl, 2.2 mM KCl, 80 µg/mL FLAG peptide, 20% glycerol and 3 mM DTT.